Celsion Expects To Begin Enrollment Of Phase I Portion Of The OVATION II Study Of GEN-1 During First Half Of 2018 In Up to 90 Patients, Says Phase I/II Study Will Be Powered To Show A 33% Improvement In The Primary Endpoint, Progression Free Survival